Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
Acumen Pharmaceuticals presented new data at AAIC 2026 demonstrating that its EBD candidate ACU401 achieved up to 40-fold greater frontal cortex exposure in non-human primates compared to native antibodies. The study, conducted with partner JCR Pharmaceuticals, showed improved brain penetration via the transferrin receptor without hematological safety signals, supporting the potential for low-volume delivery devices.
Key figures
- Drug Name
- ACU401
- Phase Of Trial
- Phase 2
- Altidude ad enrollment
- 542
- Patient interview count
- 38
- Acu401 fold increase exposure
- 40-fold higher at 24 hours
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.